Does Medicaid Cover GLP-1 in Virginia: Diabetes, Weight Loss, MASH

Yes, Virginia Medicaid does cover GLP-1 drugs, but what you have to prove depends entirely on why the drug is being prescribed. For type 2 diabetes, coverage is required by federal law and the path is relatively simple. For weight loss, coverage exists but is tightly restricted by BMI thresholds, a required trial of another weight loss drug, and a provider attestation that your obesity is disabling. Virginia also covers GLP-1s for a few other FDA-approved uses, including cardiovascular risk reduction, obstructive sleep apnea, and a form of fatty liver disease.

If the Prescription Is for Type 2 Diabetes

Federal Medicaid rules require states to cover most FDA-approved outpatient drugs, so Virginia Medicaid must cover GLP-1 receptor agonists prescribed for type 2 diabetes. The Department of Medical Assistance Services (DMAS) still applies service authorization to confirm appropriate use. In practice you need a confirmed diabetes diagnosis and documentation that traditional drug treatments did not work.¹

The Cardinal Care preferred drug list identifies Trulicity and Victoza as covered GLP-1s in the incretin mimetic category, each with prior authorization, age limits, and quantity limits. Other GLP-1s used for diabetes, such as Ozempic, Mounjaro, Rybelsus, Byetta, and Bydureon Bcise, may be available as non-preferred drugs, which means extra authorization steps.²¹

If the Prescription Is for Weight Loss

Weight loss coverage is optional under federal Medicaid law, and Virginia has chosen to offer it only in narrowly defined circumstances. The current fee-for-service criteria, effective June 23, 2023, treat GLP-1s as second-line therapy. To qualify, you must meet all of the following:³

A BMI of at least 40, or at least 35 with two or more chronic conditions.
Documented attempts at lifestyle changes, including diet and exercise, that did not produce weight loss.
A trial of a non-GLP-1 weight loss medication in the six months before the request, which did not work.
An attestation from your prescriber that your obesity is disabling and life-threatening.
Records supporting each of the above.

KFF. Medicaid Coverage of and Spending on GLP-1s notes that the federal Medicaid Drug Rebate Program allows states to exclude weight loss drugs outright, so Virginia’s decision to cover them, even with limits, is more generous than most states.

If You Are in a Managed Care Plan

Most Virginia Medicaid enrollees get their benefits through one of five managed care organizations: Aetna Better Health of Virginia, Anthem HealthKeepers Plus, Humana Healthy Horizons, Sentara Community Plan, and UnitedHealthcare Community Plan of Virginia. Each MCO runs its own formulary.⁴

The MCO rules are close to the state criteria but differ on BMI. Anthem HealthKeepers Plus, UnitedHealthcare Community Plan, and Aetna Better Health all cover Wegovy, Saxenda, and Zepbound for weight management as non-preferred drugs requiring prior authorization, and they use a BMI above 40 with no additional risk factors, or a BMI above 37 with at least one risk factor such as high blood pressure, type 2 diabetes, or dyslipidemia.⁵⁶⁷

Keeping Coverage: The Renewal Rules

Initial authorization for a GLP-1 weight loss drug lasts six months.⁷ To renew for another six months under the MCO rules, you must show a weight reduction of at least five percent compared to the most recent authorization period. Renewals stop once your BMI drops below 25.⁶

DMAS applies slightly different renewal thresholds by drug: Wegovy requires at least five percent weight loss from baseline, and Saxenda requires at least four percent.⁸

Adolescents

Wegovy and Saxenda are available to patients as young as 12; Zepbound requires age 18 or older.⁵ For adolescents aged 12 through 17, DMAS uses percentile-based BMI rather than fixed numbers: at or above 140 percent of the 95th percentile for age and sex with no comorbidities, or at or above 120 percent of the 95th percentile with two or more qualifying chronic conditions.⁸

Other FDA-Approved Uses Virginia Covers

Cardiovascular Risk Reduction

As of May 2026, Virginia Medicaid covers GLP-1s to reduce cardiovascular risk in overweight or obese patients. You must be at least 45 years old, have a BMI of at least 27, and have a documented history of a heart attack, stroke, or peripheral artery disease. The prescriber must be a cardiologist or vascular specialist. You cannot have had a cardiovascular event within the previous 60 days, and this specific pathway requires that you not have a diabetes diagnosis.⁹

Obstructive Sleep Apnea

Coverage is available for moderate to severe obstructive sleep apnea in patients 18 or older with a BMI of 30 or higher and a sleep study showing an apnea-hypopnea index of at least 15 events per hour. You must have tried CPAP or shown you cannot tolerate it. An adequate CPAP trial means using the device at least four hours per night on at least 70 percent of nights over two or more months. Initial authorization runs six months, with 12-month renewals if symptoms improve.¹⁰

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Coverage is available for MASH, a form of fatty liver disease. You must be 18 or older with a BMI of at least 18.5 and a confirmed MASH diagnosis showing stage F2 or F3 fibrosis, documented by liver biopsy or noninvasive imaging within the past six months. The prescription must come from a hepatologist, gastroenterologist, or liver disease specialist. Initial authorization lasts six months, with 12-month renewals if you show clinical improvement.¹¹

If Your Prior Authorization Is Denied

You can appeal. The route depends on whether you are in managed care or fee-for-service.

If you are in a managed care plan, file an internal appeal with the MCO within 60 days of the denial notice. The MCO must decide within 30 days, though it can extend the deadline by up to 14 days. If a delay could cause serious harm, request an expedited appeal and the MCO must respond within 72 hours.¹²

If the MCO’s internal appeal fails, escalate to the DMAS Appeals Division within 120 days of the MCO’s final decision. Appeals can be filed through the DMAS Appeals Information Management System portal, by mail to 600 East Broad Street in Richmond, by phone at 804-371-8488, or by email at appeals@dmas.virginia.gov.¹³ One protection matters here: if you file the appeal before the effective date of a coverage termination or reduction, your existing coverage continues until the appeal is resolved.¹²

A Change That May Be Coming

The 2026 budget session introduced a proposed amendment that would remove Virginia’s categorical exclusion of GLP-1 drugs from weight loss coverage but impose a price cap: DMAS could not list any GLP-1 on the formulary if the net price for a one-month supply exceeds $245. The amendment also authorizes the state to pursue rebates or value-based purchasing agreements with manufacturers to reach that price.¹⁴ Until any such change is enacted, the criteria described above are what govern your prescription.

1
Virginia Regulatory Town Hall. DMAS Report on Diabetic GLP-1 Medications
2
Formulary Navigator. Virginia Medicaid Cardinal Care Formulary
3
Virginia Medicaid (DMAS). Upcoming Changes to Service Authorization Criteria for Weight Loss Drugs
4
Virginia DMAS. Prescription Drug Formularies
5
Anthem Providers. Virginia Medicaid Weight Loss Management PA Form
6
UnitedHealthcare Community Plan. Virginia Weight Loss Management PA Form
7
Aetna Better Health. Virginia FIDE Medicaid Prior Authorization Criteria
8
Virginia Regulatory Town Hall. DMAS Guidance Document for Weight Loss Drug Authorization
9
Virginia Medicaid Pharmacy Services. SA Form for GLP-1 RAs for Cardiovascular Risk Reduction
10
Virginia Medicaid Pharmacy Services. SA Form for GLP-1 RAs for Obstructive Sleep Apnea
11
Virginia Medicaid Pharmacy Services. SA Form for GLP-1 RAs for MASH
12
Virginia Code Commission. 12VAC30-120-420 MCO Appeal Procedures
13
Virginia DMAS. DMAS Appeals
14
Virginia Legislative Information System. 2026 Budget Amendment HB30 Item 291 #9h